Share on StockTwits

NuVasive (NASDAQ:NUVA) is scheduled to be posting its Q114 quarterly earnings results on Tuesday, April 29th. Analysts expect NuVasive to post earnings of $0.23 per share and revenue of $171.30 million for the quarter. NuVasive has set its FY14 guidance at approx $1.06 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

NuVasive (NASDAQ:NUVA) last released its earnings data on Monday, March 3rd. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.32 by $0.05. The company had revenue of $190.80 million for the quarter, compared to the consensus estimate of $181.24 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. On average, analysts expect NuVasive to post $1.08 EPS for the current fiscal year and $1.39 EPS for the next fiscal year.

NuVasive (NASDAQ:NUVA) opened at 33.64 on Monday. NuVasive has a 1-year low of $20.45 and a 1-year high of $39.89. The stock has a 50-day moving average of $36.43 and a 200-day moving average of $33.85. The company has a market cap of $1.545 billion and a P/E ratio of 205.06.

Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. raised their price target on shares of NuVasive from $34.00 to $40.00 in a research note on Tuesday, March 4th. They now have a “neutral” rating on the stock. On the ratings front, analysts at Jefferies Group raised their price target on shares of NuVasive from $35.00 to $45.00 in a research note on Tuesday, March 4th. Finally, analysts at BMO Capital Markets raised their price target on shares of NuVasive from $30.00 to $38.00 in a research note on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $37.24.

NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.